A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Sponsors Celgene Corporation
- 09 Apr 2018 Status changed from active, no longer recruiting to discontinued.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2017 Planned End Date changed from 28 Oct 2019 to 29 Oct 2019.